Ovarian Cancer Clinical Trial
Official title:
Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining chemotherapy with peripheral stem cell
transplantation may allow patients to tolerate higher doses of chemotherapy and kill more
tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and
peripheral stem cell transplantation in treating patients who have germ cell tumors that
have not responded to previous chemotherapy.
OBJECTIVES: I. Determine the complete response rate (chemotherapy complete response,
pathological complete response, or surgical complete response) to intensive chemotherapy
with autologous peripheral blood stem cell support in patients with cisplatin resistant germ
cell tumors. II. Determine duration of complete response and survival of these patients
after this therapy. III. Determine the toxic effects of this regimen in these patients. IV.
Determine the pharmacokinetics of this regimen and the relationship between these
pharmacokinetics, nature and duration of response to treatment, and the toxic effects in
these patients.
OUTLINE: This is an open label, multicenter study. Patients receive epirubicin IV over 15
minutes and paclitaxel IV over 3 hours on day 1, then filgrastim (G-CSF) subcutaneously (SQ)
on days 5-14. Peripheral blood stem cells (PBSC) are collected on days 13 and 14. This
course is repeated beginning on day 15. Patients then undergo a three part intensification
regimen. Part I: Patients receive cyclophosphamide IV and thiotepa IV by continuous infusion
on days 34 and 35. PBSC are reinfused on day 38, and G-CSF SQ is administered from day 39
until blood cell counts recover. Part II: Patients receive etoposide IV over 2 hours,
ifosfamide IV over 4 hours, and carboplatin IV over 6 hours on days 62-66. PBSC are
reinfused on day 70, and eventually G-CSF begins on day 71. Part III: Patients receive
etoposide, ifosfamide, and carboplatin on days 90-94 as in part II. PBSC are reinfused on
day 98 and eventually G-CSF begins on day 99. Patients are followed every month for the
first year, every 2 months for the second year, every 6 months for the third and fourth
years, then annually thereafter.
PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 2 years.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |